Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8533386 | 1.00 | FFAR3 (0.38) | FFAR3CYP2C19CYP2D6AKR1C1TSHR | |
| SCHEMBL8907359 | 0.97 | FFAR3 (0.40) | FFAR3CYP2C19CYP2D6AKR1C1TSHR | |
| SCHEMBL127199 | 0.97 | FFAR3 (0.40) | FFAR3CYP2C19CYP2D6AKR1C1TSHR | |
| Hydrochloric Acid SCHEMBL1189681 | 0.93 | FFAR3 (0.38) | FFAR3CYP2C19CYP2D6AKR1C1TSHR | |
| Bromide SCHEMBL16086037 | 0.93 | FFAR3 (0.38) | FFAR3CYP2C19CYP2D6AKR1C1TSHR | |
| SCHEMBL9619104 | 0.93 | FFAR3 (0.38) | FFAR3CYP2C19CYP2D6AKR1C1TSHR | |
| Hydrochloric Acid SCHEMBL809129 | 0.93 | FFAR3 (0.38) | FFAR3CYP2C19CYP2D6AKR1C1TSHR | |
| SCHEMBL7766381 | 0.93 | FFAR3 (0.38) | FFAR3CYP2C19CYP2D6AKR1C1TSHR | |
| SCHEMBL5367504 | 0.93 | FFAR3 (0.38) | FFAR3CYP2C19CYP2D6AKR1C1TSHR | |
| SCHEMBL21295011 | 0.93 | CYP2C19 (0.40) | FFAR3CYP2C19CYP2D6AKR1C1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115165771-A | Control method for silver content in platinum anticancer drug synthesized by silver salt method | 昆明贵研药业有限公司 | 2022-10-11 | — | — | CN | claimed |
| CN-108521780-A | The method that one kettle way prepares bis-dicarboxylic diamino platinum (II) derivative | 昆明贵研药业有限公司 | 2018-09-11 | — | — | CN | claimed |
| JP-2028134-A | — | — | None | — | — | JP | disclosed |
| JP-2028135-A | — | — | None | — | — | JP | disclosed |
| JP-62298596-A | — | — | None | — | — | JP | disclosed |
| CN-108521780-B | Method for preparing bis-dicarboxylic acid diammine platinum (II) derivative by one-pot method | 昆明贵研药业有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-106543233-B | Chiral binuclear platinum complex containing unsaturated bond and preparation method and application thereof | 昆明理工大学 | 2021-04-09 | — | — | CN | disclosed |
| CN-106565859-B | Cyclodextrin-bonded object of a kind of chirality platinum-and its preparation method and application | 昆明理工大学 | 2019-09-27 | — | — | CN | disclosed |
| WO-2019161526-A1 | ONE-POT METHOD FOR PREPARING TWIN DICARBOXYLIC ACID DIAMINE COMPLEX PLATINUM (II) DERIVATIVES | 昆明贵研药业有限公司 | 2019-08-29 | — | — | WO | disclosed |
| CN-108521780-A | The method that one kettle way prepares bis-dicarboxylic diamino platinum (II) derivative | 昆明贵研药业有限公司 | 2018-09-11 | — | — | CN | disclosed |
| CN-106543233-A | The chiral binuclear platinum complex of one class containing unsaturated bond and its preparation method and application | 昆明理工大学 | 2017-03-29 | — | — | CN | disclosed |
| EP-1282631-B1 | METHODS OF SYNTHESIS OF RADIOLABELLED PLATINUM CHEMOTHERAPEUTIC AGENTS | AUSTRALIAN NUCLEAR SCIENCE TEC (AU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007128158-A1 | TRANSITION METAL COMPLEXES FOR INHIBITING RESISTANCE IN THE TREATMENT OF CANCER AND METASTASIS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2007-11-15 | — | — | WO | disclosed |
| US-7108845-B2 | Methods of synthesis and use of radiolabelled platinum chemotherapeutic agents | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 2006-09-19 | — | — | US | disclosed |
| US-20030103896-A1 | Methods of synthesis and use of radiolabelled platinum chemotherapeutic agents | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 2003-06-05 | — | — | US | disclosed |
| EP-1282631-A1 | METHODS OF SYNTHESIS AND USE OF RADIOLABELLED PLATINUM CHEMOTHERAPEUTIC AGENTS | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001070755-A1 | METHODS OF SYNTHESIS AND USE OF RADIOLABELLED PLATINUM CHEMOTHERAPEUTIC AGENTS | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 2001-09-27 | — | — | WO | disclosed |
| JP-H0228134-A | PREPARATION OF CARBOXYLATO(DIAMINE) PLATINUM | CHUGAI PHARMACEUT CO LTD | 1990-01-30 | — | — | JP | disclosed |
| JP-H0228135-A | PREPARATION OF PLATINUM COMPLEX | CHUGAI PHARMACEUT CO LTD | 1990-01-30 | — | — | JP | disclosed |
| JP-S62298596-A | PRODUCTION OF PLATINUM COMPLEX | CHUGAI PHARMACEUT CO LTD | 1987-12-25 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030103896-A1 | Methods of synthesis and use of radiolabelled platinum chemotherapeutic agents | REV1, IDH1, PAICS | FFAR3 4716/4885CYP2C19 1462/4885CYP2D6 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.